Utility of index lesion volume assessed by multiparametric MRI combined with Gleason grade for assessment of lymph node involvement in patients with high-risk prostate cancer.

Abstract

PURPOSE\nWe examined the potential predictors of lymph node involvement and evaluated whether index lesion volume assessed using multiparametric magnetic resonance imaging is associated with lymph node involvement among patients with high-risk prostate cancer.\n\n\nMETHODS\nExtended pelvic lymph node dissection was used to evaluate patients with lymph node involvement. We retrospectively analyzed consecutive 102 patients with high-risk prostate cancer who underwent extended pelvic lymph node dissection at our institution between 2011 and 2017. To evaluate the index lesion volume at multiparametric magnetic resonance imaging (mrV), lesions were manually contoured on each T2-weighted axial slice in combination with diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging and integrated using image analysis software. Logistic regression analysis was performed to identify predictors of lymph node involvement.\n\n\nRESULTS\nThe median mrV was 1.4\xa0ml (range 0-30.1\xa0ml), and the median number of resected lymph nodes was 14 (range 7-38). Among 102 patients, 28 (28%) had lymph node involvement. Multivariate analysis identified significant predictors of lymph node involvement as follows: biopsy Gleason-grade group 5 (odds ratio\xa0=\xa017.2; 95% confidence interval, 2.1-299.0; P\xa0=\xa00.005), preoperative mrV (odds ratio\xa0=\xa01.14; 95% confidence interval, 1.02-1.30; P\xa0=\xa00.025) and percentage of positive cores with highest Gleason-grade group (odds ratio\xa0=\xa01.05; 95% confidence interval, 1.01-1.10; P\xa0=\xa00.005). Lymph node involvement was prevalent (69%) among tumors with Gleason-grade group 5 and mrV ≥3.4\xa0ml, but was infrequently (10%) present among tumors with Gleason-grade group ≤4 and mrV <3.4\xa0ml.\n\n\nCONCLUSIONS\nThe combination of biopsy Gleason-grade and mrV may serve as a useful tool to stratify patients according to their risk of nodal metastases.